Kalaris Therapeutics KLRS
NASDAQ KLRS
$2.02 -0.05 (-2.42%)
As of: Oct 21, 2026 · 1:18 PM EDT

Kalaris Therapeutics (KLRS) Total Debt (2024)

Updated

Kalaris Therapeutics (KLRS) reported Total Debt of $19.54 million for Q4 2024.

Analysis

Kalaris Therapeutics (KLRS) Total Debt (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,134.96 Bn 1,103.55 Bn 19.71 Bn 54.91 Bn
2 Johnson & Johnson 616.51 Bn 535.04 Bn 17.26 Bn 49.04 Bn
3 AbbVie 501.10 Bn 474.21 Bn 12.70 Bn 70.82 Bn
4 Merck 367.09 Bn 321.47 Bn 12.21 Bn 53.91 Bn
5 Novartis Ag 298.10 Bn 262.09 Bn 11.24 Bn 9.59 Bn
6 Astrazeneca 261.72 Bn 235.40 Bn 12.86 Bn 32.35 Bn
7 Amgen 235.73 Bn 191.13 Bn 7.24 Bn 57.30 Bn
8 Gilead Sciences 190.64 Bn 164.84 Bn 6.22 Bn 26.25 Bn
9 Pfizer 169.63 Bn 116.28 Bn 10.94 Bn 63.19 Bn
10 Kalaris Therapeutics 47.83 Mn -45.67 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 19.54 Mn
API Access

Kalaris Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=KLRS&period=max&api_key=YOUR_API_KEY